Similar Articles

  • Interpreting the COMET trial

    W.H. Wilson Tang, MD, Michael Militello, PharmD and Gary S. Francis, MD
    • Cleveland Clinic Journal of Medicine December 2003, 70 (12) 1081-1087;
    • Although survival was better with carvedilol than with immediate-release metoprolol tartrate, we must increase the use of any approved beta-blocker in heart failure.

  • Interpreting the ASTEROID Trial

    Ilke Sipahi, MD, Stephen J. Nicholls, MBBS, PhD, E. Murat Tuzcu, MD and Steven E. Nissen, MD
    • Cleveland Clinic Journal of Medicine October 2006, 73 (10) 937-944;
    • The optimal strategy for lipid-lowering in patients with coronary artery disease may be to aim for the lowest low-density lipoprotein cholesterol level that can be attained without adverse effects.

  • Interpreting the Enhance Trial

    Michael H. Davidson, MD
    • Cleveland Clinic Journal of Medicine July 2008, 75 (7) 479-491;
    • The impact of the ENHANCE trial reveals more about the political climate than it does about the effects of ezetimibe on the progression of atherosclerosis.

  • Interpreting the Courage Trial

    William E. Boden, MD
    • Cleveland Clinic Journal of Medicine September 2007, 74 (9) 623-633;
    • We found that as an initial management strategy in patients with stable coronary artery disease, percutaneous coronary intervention did not reduce the incidence of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy.

  • Interpreting the Courage Trial

    Deepak L. Bhatt, MD
    • Cleveland Clinic Journal of Medicine September 2007, 74 (9) 618-620;
    • We are fortunate to have a point-counterpoint between Dr. William Boden, the principal investigator of the Clinical Outcomes Utilizing Percutaneous Coronary Revascularization and Aggressive Drug Evaluation (COURAGE) trial, and Dr. Dean Kereiakes, a leading interventional cardiologist.

  • Interpreting the Courage Trial

    Dean J. Kereiakes, MD
    • Cleveland Clinic Journal of Medicine September 2007, 74 (9) 637-642;
    • COURAGE had several problems, and tells us nothing new.

  • The PARADIGM-HF trial (October 2015)

    Robert P. Blankfield, MD, MS
    • Cleveland Clinic Journal of Medicine March 2016, 83 (3) 167;
    • DOI: https://doi.org/10.3949/ccjm.83c.03001
    • A reader comments on the fi ndings of the PARADIGM-HF trial (October 2015).

  • In reply: The PARADIGM-HF trial (October 2015)

    Marwa A. Sabe, MD, MPH, Miriam S. Jacob, MD and David O. Taylor, MD
    • Cleveland Clinic Journal of Medicine March 2016, 83 (3) 167-168;
    • DOI: https://doi.org/10.3949/ccjm.83c.03002
  • A new look at the old mosaic

    Jacques Genest, C. C., M.D
    • Cleveland Clinic Journal of Medicine June 1984, 51 (2) 449-461;
  • Nelson’s syndrome; a new look

    Leslie R. Sheeler, M.D, Raymond F. Grenfell Jr., M.D, O. Peter Schumacher, M.D., Ph.D and Manjula S. Kumar, Ph.D
    • Cleveland Clinic Journal of Medicine December 1980, 47 (4) 299-304;
Previous